Aktienanalyse zu TherapeuticsMD Inc (TXMD)TXMDTherapeuticsMD Inc

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

TherapeuticsMD Inc (TXMD) is currently trading at $1.70, which is significantly below its 52-week high of $2.95, indicating potential upside. However, the RSI is at 35.87, suggesting the stock is in oversold territory, but the recent 5-day change is down 5.56%, indicating negative momentum. The forward P/E ratio is a very low 2.33, suggesting the stock may be undervalued, but the company has a history of inconsistent earnings, with a net loss of $619,000 in Q4 2025. The main risk is the company's negative net income trend, with a net loss of $619,000 in the last quarter reported, which could impact future performance and investor confidence.

9 analysts cover TXMD: 8 rate it Buy, 1 Hold and 0 Sell.